|
AU2019305055A1
|
|
Method and system for assessing a coronary stenosis
|
|
SG11202011261PA
|
|
Urolithin a and derivatives thereof for use in therapy
|
|
AU2015252158A1
|
|
Human facilitating cells and uses thereof
|
|
AU2015213389A1
|
|
Human facilitating cells
|
|
AU2012225574A1
|
|
Predictive marker of DNMT1 inhibitor therapeutic efficacy and methods of using the marker
|
|
AU2011293202A1
|
|
Compositions and methods for treating bone defects
|
|
AU2009324641A1
|
|
Somatic cell-derived pluripotent cells and methods of use therefor
|
|
AU2009255663A1
|
|
Human facilitating cells
|
|
AU2009246822A1
|
|
Site specific fluorescence marking and contrast marker for same
|
|
AU2009223653A1
|
|
Methods and compositions for controlled delivery of phytochemical agents
|
|
AU2008218188A1
|
|
Methods and compounds for the targeted delivery of agents to bone for interaction therewith
|
|
AU2008207735A1
|
|
Modification of exosomal components for use as a vaccine
|
|
AU2005321808A1
|
|
Genetic markers of schizophrenia
|
|
AU2002326573B2
|
|
Use of S-nitrosothiol signaling to treat disordered control of breathing
|
|
AU2002216763B2
|
|
Alteration of cell membrane
|
